Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20401006 | 1.00 | CTSL (0.53) | CTSLCTSSCASP3KMT2ACYP3A4 | |
| SCHEMBL30638167 | 1.00 | CTSL (0.53) | CTSLCTSSCASP3KMT2ACYP3A4 | |
| SCHEMBL29401180 | 1.00 | CTSL (0.53) | CTSLCTSSCASP3KMT2ACYP3A4 | |
| SCHEMBL13695275 | 1.00 | CTSL (0.53) | CTSLCTSSCASP3KMT2ACYP3A4 | |
| SCHEMBL18718110 | 0.90 | CASP3 (0.50) | CTSLCTSSCASP3KMT2ACYP3A4 | |
| SCHEMBL31000661 | 0.90 | CASP3 (0.49) | CTSLCTSSCASP3KMT2ACYP3A4 | |
| SCHEMBL25718153 | 0.88 | CASP3 (0.52) | CTSLCTSSCASP3KMT2ACYP3A4 | |
| SCHEMBL31000521 | 0.88 | KMT2A (0.48) | CASP3KMT2ACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL31000700 | 0.88 | KMT2A (0.48) | CASP3KMT2ACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25718152 | 0.88 | CASP3 (0.52) | CTSLCTSSCASP3KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076299-B2 | Method for producing peptide thioester | RIKEN (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20090240034-A1 | METHOD FOR PRODUCING PEPTIDE THIOESTER | RIKEN (JP) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240034-A1 | METHOD FOR PRODUCING PEPTIDE THIOESTER | PTMS, PPT1, NGLY1 | CTSL 502/4885CTSS 945/4885CASP3 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.